A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel cell carcinoma

ID Number 15-0591

Principal Investigator(s)
Philip Friedlander

Department(s) or Division(s)
Hematology and Medical Oncology


The study drug is an investigational drug that is being evaluated for the treatment of patients with Merkel cell carcinoma.  Investigational means that it has not been approved by the U.S. Food and Drug Administration (FDA) and is still being tested for safety and effectiveness.  Information gathered from this study will be sent to the various health authorities.

The main purpose of this research study is to find out whether the study drug has anti-cancer effects.  Additional purposes of the study are to assess side effects of MSB0010718C, and to find out how the study drug is processed by the body (this is called pharmacokinetic or PK research).

Contact Information
Linda Sacris
(212) 824-7309

Recruiting Patients: No